67 results
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
4:35pm
Symptom Diary
Long-Term Data from Open-Label ACROBAT Advance Extension Study Demonstrated Durable Safety, IGF-1, and Symptom Control at Up to 42-Months … PATHFNDR-1 trial, and interim long-term efficacy and safety results at 42 months from the open-label ACROBAT Advance extension study. The data were presented
8-K
EX-99.3
CRNX
Crinetics Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
4:35pm
from product sales to support growth 2024 Continuous stream of clinical catalysts New assets emerging from Strategic Approach to Growing Long-term Value
8-K
CRNX
Crinetics Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
4:35pm
-2 trial, a new analysis of patient reported outcome data from the Phase 3 PATHFNDR-1 trial, and interim long-term efficacy and safety results at 42
8-K
EX-99.1
63nhvc
9 May 24
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results
4:12pm
8-K
EX-99.1
y8s353w
8 May 24
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
5:00pm
S-3ASR
5229mks
19 Mar 24
Automatic shelf registration
4:05pm
8-K
EX-99.2
gm7f 7u2f
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
EX-99.2
vwup6u5g
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-99.1
lvnyecvdylej kamn1pb
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-10.1
11yjsmrw4kih2luf8ju8
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-99.1
mbag2tf4a
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.2
dnpu 9e3wqtxr2m
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
inodp6vjk8mbwddfmbu
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-99.1
8qdc9onq eiplqtry
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm